Metastatic breast cancer: chemotherapy or anti-hormonal treatment in combination with ribociclib

SAKK 21/18

Coordinating investigator

Prof. Dr. med.
Brustzentrum Ostschweiz AG
+41 71 552 33 33

Although progress has been made in the treatment of breast cancer over the past few decades, metastatic breast cancer remains an incurable disease. Average overall survival rates are 2–4 years, with only 25% surviving for five years.

Many oncologists primarily use chemotherapy to treat patients with metastases in the lung/liver rather than an endocrine therapy (glossary: endocrine: relating to the hormonal system). However, findings from clinical trials indicate that endocrine therapy is associated with a better quality of life, fewer side-effects and a higher level of satisfaction with treatment than chemotherapy.

In trial SAKK 21/18 patients will be assigned to one of two groups at random: They will receive either a combination of the medicine ribociclib and endocrine therapy, or chemotherapy. The trial will investigate how the treatment affects the course of the disease, the patient's quality of life and the prognosis.

All trials